NICE draft guidance has recommended the anti-blood clotting drug edoxaban (Lixiana, Daiichi Sankyo) as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) who have one or more further risk factors.
Professor Carole Longson, NICE Health Technology Evaluation Centre director, commented: “Because edoxaban doesn’t require frequent blood tests to monitor treatment, it represents a significant potentialbenefit for many people with NVAF. There was also evidence that edoxaban had nearly half the rate of haemorrhagicstroke events compared to warfarin.”
